



# Lyka Labs Limited



## MANUFACTURERS OF PHARMACEUTICALS

Admn. Office : 101, Shiv Shakti Industrial Estate, Sir M. V. Road,  
Andheri (E), Mumbai-400 059. • Phones : 6611 2200 • Fax : 6611 2248 / 49

Website : lykalabs.com • Email : enquiry@lykalabs.com

### STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2012

Particular	Rs. In Lacs				
	Year to date figure for current period Ended 30-Jun-2012 (3 Months) (Unaudited)	Preceding 3 Months Ended 31-Mar-2012 (Unaudited)	Corresponding 3 Months ended 30-Jun-2011 in the previous year (Unaudited)	Year to date figure for Previous period Ended 31-Mar-2012 (18 Months) (Unaudited)	Previous Accounting year ended 30-Sept-2010 (12 Months) (Audited)
<b>1 Income from operations</b>					
(a) Net Sales/Income from operations (Net of excise duty)	1979.80	2191.16	2419.97	13434.40	11582.01
(b) Other Operating Income	142.16	79.15	100.28	561.89	287.92
<b>Total income from operations (net)</b>	<b>2,121.96</b>	<b>2270.31</b>	<b>2520.25</b>	<b>13996.29</b>	<b>11869.93</b>
<b>2 Expenses</b>					
(a) Cost of Materials Consumed	927.89	1299.20	1027.68	6745.15	5215.50
(b) Purchase of traded goods	226.18	293.00	966.38	2660.66	2820.13
(c) Change in inventories of finished goods, work-in-progress and stock-in-trade,	59.83	-116.37	-160.99	-148.81	-188.56
(d) Employee benefits expense	265.15	275.61	307.98	1689.64	1030.84
(e) Depreciation and amortisation expense	78.01	91.37	88.41	541.15	339.59
(f) Other expenses	365.26	401.53	429.87	2190.01	1447.51
<b>Total expenses</b>	<b>1922.32</b>	<b>2244.34</b>	<b>2659.33</b>	<b>13677.80</b>	<b>10665.01</b>
<b>3 Profit/(Loss) from Operations before Other Income, Finance cost and Exceptional Items (1-2)</b>	<b>199.64</b>	<b>25.97</b>	<b>-139.08</b>	<b>318.49</b>	<b>1204.92</b>
<b>4 Other Income</b>	<b>50.41</b>	<b>178.24</b>	<b>66.06</b>	<b>478.89</b>	<b>220.18</b>
<b>5 Profit/(Loss) from ordinary activities before finance cost and exceptional Items (3+4)</b>	<b>250.05</b>	<b>204.21</b>	<b>-73.02</b>	<b>797.38</b>	<b>1425.10</b>
<b>6 Finance costs</b>	<b>368.33</b>	<b>357.29</b>	<b>379.13</b>	<b>2244.55</b>	<b>1112.13</b>
<b>7 Profit/(Loss) from ordinary activities after finance cost but before exceptional Items (5+6)</b>	<b>-118.28</b>	<b>-153.08</b>	<b>-452.15</b>	<b>-1447.17</b>	<b>312.97</b>
<b>8 Exceptional Items (Net)</b>	<b>49.72</b>	<b>746.91</b>	<b>0.00</b>	<b>881.24</b>	<b>-138.24</b>
<b>9 Profit/(Loss) from Ordinary Activities before tax (7+8)</b>	<b>-68.56</b>	<b>593.84</b>	<b>-452.15</b>	<b>-565.93</b>	<b>174.73</b>
<b>10 Tax Expenses</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>-6.26</b>
<b>11 Net Profit/(Loss) from Ordinary activities after tax (9+10)</b>	<b>-68.56</b>	<b>593.84</b>	<b>-452.15</b>	<b>-565.93</b>	<b>180.99</b>
<b>12 Extraordinary Item (net of tax expenses)</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
<b>13 Net Profit/(Loss) for the period (11+12)</b>	<b>-68.56</b>	<b>593.84</b>	<b>-452.15</b>	<b>-565.93</b>	<b>180.99</b>
<b>14 Paid up equity share capital (face value Rs.10/- per share)</b>	<b>2158.00</b>	<b>2158</b>	<b>2158.00</b>	<b>2158.00</b>	<b>2158.00</b>
<b>15 Reserve excluding Revaluation Reserve as per balance sheet of previous accounting year</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>5217.16</b>
<b>16 i. Earnings Per Share (before extraordinary items) (of Rs 10/-each (not annualised))</b>					
(a) Basic	-0.32	2.75	-2.10	-2.62	0.84
(b) Diluted	-0.32	2.75	-2.10	-2.62	0.84
<b>16 ii. Earnings Per Share (After extraordinary items) (of Rs 10/-each (not annualised))</b>					
(a) Basic	-0.32	2.75	-2.10	-2.62	0.84
(b) Diluted	-0.32	2.75	-2.10	-2.62	0.84



# Lyka Labs Limited



MANUFACTURERS OF PHARMACEUTICALS

Admn. Office : 101, Shiv Shakti Industrial Estate, Sir M. V. Road,  
Andheri (E), Mumbai-400 059. • Phones : 6611 2200 • Fax : 6611 2248 / 49

Website : lykalabs.com • Email : enquiry@lykalabs.com

## STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2012

Particular	Year to date figure for current period Ended 30-Jun-2012 (3 Months)	Preceding 3 Months Ended 31-Mar-2012	Corresponding 3 Months ended 30-Jun-2011 in the previous year	Year to date figure for Previous period Ended 31-Mar-2012 (18 Months)	Rs. In Lacs
					Previous Accounting year ended 30-Sept-2010 (12 Months)
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
<b>A PARTICULARS OF SHAREHOLDING</b>					
1 Public Shareholding					
Number of shares	16552735	16552735	16552735	16552735	16552735
percentage of shareholding	76.70	76.7	76.70	76.70	76.70
2 Promoters and promoter group - Shareholding					
a. Pledged / Encumbered					
- Numbers of Shares	4965615	4965615	4783615	4965615	4133415
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	98.77	98.77	95.15	98.77	82.22
- Percentage of shares (as a % of the total share capital of the company)	23.01	23.01	22.17	23.01	19.15
b. Non - encumbered					
- Number of shares	61650	61650	243650	61650	893850
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	1.23	1.23	4.85	1.23	17.78
- Percentage of shares (as a % of the total share capital of the company)	0.29	0.29	1.14	0.29	4.15

PARTICULARS	
<b>B INVESTOR COMPLAINTS</b>	3 Month Ended
Pending at the beginning of the quarter	-
Received during the quarter	-
Disposed of during the quarter	-
Remaining unresolved at the end of the quarter	-



Notes:

1. The above results were duly considered by the Audit Committee on 14<sup>th</sup> August, 2012, and taken on record by the Board of Directors of the Company along with Limited Review Report carried out by the Auditors at its meeting held on 14<sup>th</sup> August, 2012.
2. During the Quarter the Company has charged Rs. 18.79 lacs being depreciation on revalued assets.
3. The Company has capitalised a sum of Rs. 15.06 lacs being Interest towards the Term Loan for Tarapur Upgradation, during the quarter.
4. The Company's factory at Tarapur is under upgradation. In view of this the production has been suspended.
5. The Company has one Single Segment "Pharmaceuticals".
6. Previous periods figures have been regrouped/rearranged wherever necessary.

For L YKA LABS LIMITED

(N. I. GANDHI)

Chairman & Managing Director

Mumbai  
14-Aug-12



# Lyka Labs Limited



## MANUFACTURERS OF PHARMACEUTICALS

Admn. Office : 101, Shiv Shakti Industrial Estate, Sir M. V. Road,  
Andheri (E), Mumbai-400 059. • Phones : 6611 2200 • Fax : 6611 2248 / 49

Website : lykalabs.com • Email : enquiry@lykalabs.com

### STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2012 (Rs.in Lacs)

Particulars	3 Months Ended 30/06/2012	Preceding 3 Months Ended 31/03/2012	Corresponding 3 Months Ended 30/06/2011 in the previous year	Year To Date Figures For Previous period ended 31/03/2012 (18 months)	Previous Accounting Year ended 30/09/2010 (12 months)
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
<b>1 Income from operations</b>					
(a) Net Sales/Income from operations (Net of excise duty)	3,012.71	2,762.47	2,742.13	16200.96	13912.32
(b) Other Operating Income	163.14	134.62	117.63	706.95	820.15
<b>Total income from operations (net)</b>	<b>3,175.85</b>	<b>2,897.09</b>	<b>2,859.76</b>	<b>16,907.91</b>	<b>14,732.47</b>
<b>2 Expenses</b>					
(a) Cost of Materials Consumed	927.89	1,299.20	1,027.68	6745.15	5215.50
(b) Purchase of traded goods	659.26	456.05	1,099.42	3644.34	3511.22
(c) Change in inventories of finished goods, work-in-progress and stock-in-trade,	29.07	-130.75	-160.99	-171.58	-183.12
(d) Employee benefits expense	298.83	341.19	310.49	1924.82	1176.90
(e) Depreciation and amortisation expense	123.54	144.74	141.33	860.05	568.56
(f) Other expenses	579.55	637.66	661.95	3395.18	2469.28
<b>Total expenses</b>	<b>2,618.14</b>	<b>2,748.09</b>	<b>3,079.88</b>	<b>16397.96</b>	<b>12758.34</b>
<b>3 Profit/(Loss) from Operations before Other Income, Finance cost and Exceptional items (1-2)</b>	<b>557.71</b>	<b>149.00</b>	<b>-220.12</b>	<b>509.95</b>	<b>1974.13</b>
4 Other Income	62.73	123.59	66.88	412.90	150.56
<b>5 Profit/(Loss) from ordinary activities before finance cost and exceptional items (3+4)</b>	<b>620.44</b>	<b>272.59</b>	<b>-153.24</b>	<b>922.85</b>	<b>2124.69</b>
6 Finance costs	487.09	550.47	447.87	3026.03	1719.57
<b>7 Profit/(Loss) from ordinary activities after finance costs but before exceptional items (5+6)</b>	<b>133.35</b>	<b>-277.88</b>	<b>-601.11</b>	<b>-2103.18</b>	<b>405.12</b>
8 (i) Exceptional Items (Net)	49.72	1,159.11	0.00	1273.06	-138.24
(ii) Provision for Taxation of earlier years	0.00	0.00	0.00	0.00	6.26
<b>9 Profit/(Loss) from Ordinary Activities before tax (7+8)</b>	<b>183.07</b>	<b>881.23</b>	<b>-601.11</b>	<b>-830.12</b>	<b>273.14</b>
10 Tax Expenses	0.00	0.00	0.00	0.00	0.00
<b>11 Net Profit/(Loss) from Ordinary activities after tax (9+10)</b>	<b>183.07</b>	<b>881.23</b>	<b>-601.11</b>	<b>-830.12</b>	<b>273.14</b>
12 Extraordinary item (net of tax expenses)	0.00	0.00	0.00	0.00	0.00
<b>13 Net Profit/(Loss) for the period (11+12)</b>	<b>183.07</b>	<b>881.23</b>	<b>-601.11</b>	<b>-830.12</b>	<b>273.14</b>
14 Share of Profit/(Loss) of associates	0.00	0.00	0.00	0.00	0.00
15 Minority interest	0.00	0.00	0.00	0.00	0.00



# Lyka Labs Limited



## MANUFACTURERS OF PHARMACEUTICALS

Admn. Office : 101, Shiv Shakti Industrial Estate, Sir M. V. Road,  
Andheri (E), Mumbai-400 059. • Phones : 6611 2200 • Fax : 6611 2248 / 49

Website : lykalabs.com • Email : enquiry@lykalabs.com

### STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2012 (Rs.in Lacs)

Particulars	3 Months Ended 30/06/2012	Preceding 3 Months Ended 31/03/2012	Corresponding 3 Months Ended 30/06/2011 in the previous year	Year To Date Figures For Previous period ended 31/03/2012 (18 months)	Previous Accounting Year ended 30/09/2010 (12 months)
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
16 Net Profit/ (Loss) after taxes, minority interest and share of profit / (loss) of associates (13+14+15)	183.07	881.23	-601.11	-830.12	273.14
17 Paid up equity share capital ( face value Rs.10/- per share)	2158.00	2158.00	2158.00	2158.00	2158.00
18 Reserve excluding Revaluation Reserve as per Balance Sheet of previous accounting year	0.00	0.00	0.00	0.00	7965.54
19 i. Earnings Per Share (before extraordinary items) (of Rs 10/-each (not annualised)					
(a) Basic	0.85	4.08	-2.79	-3.85	1.27
(b) Diluted	0.85	4.08	-2.79	-3.85	1.27
19 ii. Earnings Per Share (After extraordinary items) (of Rs 10/-each (not annualised)					
(a) Basic	0.85	4.08	-2.79	-3.85	1.27
(b) Diluted	0.85	4.08	-2.79	-3.85	1.27
<b>A PARTICULARS OF SHAREHOLDING</b>					
1 Public Shareholding					
- Number of shares	16552735	16552735	16552735	16552735	16552735
- Percentage of shareholding	76.70	76.70	76.70	76.70	76.70
2 Promoters and promoter group - Shareholding					
a. Pledged / Encumbered					
- Numbers of Shares	4965615	4965615	4783615	4965615	4133415
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	98.77	98.77	95.15	98.77	82.22
- Percentage of shares (as a % of the total share capital of the company)	23.01	23.01	22.17	23.01	19.15
b. Non - encumbered					
- Number of shares	61650	61650	243650	61650	893850
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	1.23	1.23	4.85	1.23	17.78
- Percentage of shares (as a % of the total share capital of the company)	0.29	0.29	1.14	0.29	4.15

PARTICULARS	3 Month ended
<b>B INVESTOR COMPLAINTS</b>	
Pending at the beginning of the quarter	-
Received during the quarter	-
Disposed of during the quarter	-
Remaining unresolved at the end of the quarter	-



Notes:

1. The above results were duly considered by the Audit Committee on 14<sup>th</sup> August, 2012, and taken on record by the Board of Directors of the Company along with Limited Review Report carried out by the Auditors at its meeting held on 14<sup>th</sup> August, 2012.
2. Limited Review financial results for the quarter ended 30/06/2012 have been consolidated with that of Lyka BDR International Ltd., as approved by their Board.
3. During the quarter Company has charged Rs. 18.79 lacs being depreciation on revalued assets.
4. The Company has capitalised a sum of Rs. 15.06 lacs being Interest towards the Term Loan for Tarapur Upgradation, during the quarter.
5. The Company's factory at Tarapur is under upgradation. In view of this, the production has been suspended.
6. The Company has one Single Segment "Pharmaceuticals".
7. Previous periods figures have been regrouped/rearranged wherever necessary.

For L YKA LABS LIMITED

(N. I. GANDHI)

Chairman & Managing Director

Mumbai  
14-Aug-12.